NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 66
(Total Views: 281)
Posted On: 01/08/2021 3:26:42 PM
NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the momentum and wasted no time in making an impact with the announcement of a transformative in-licensing agreement with First Wave Bio, bringing in a new asset and two new GI indications into our development fold,” Sapirstein states in the letter. “AzurRx is a fundamentally stronger company today compared to 12 months ago, from a strategic, operational and financial perspective. We now have three targeted, non-systemic clinical-stage GI assets in our pipeline that address significant unmet clinical needs in potential billion-dollar markets. I believe we are poised to increase shareholder value. The Company recently raised capital in order to pay for the up-front licensing opportunity, without having to impact the budget for our MS1819 clinical timelines. In the long run, AzurRx is much better positioned to provide valuable products with significant market opportunities into the GI space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the momentum and wasted no time in making an impact with the announcement of a transformative in-licensing agreement with First Wave Bio, bringing in a new asset and two new GI indications into our development fold,” Sapirstein states in the letter. “AzurRx is a fundamentally stronger company today compared to 12 months ago, from a strategic, operational and financial perspective. We now have three targeted, non-systemic clinical-stage GI assets in our pipeline that address significant unmet clinical needs in potential billion-dollar markets. I believe we are poised to increase shareholder value. The Company recently raised capital in order to pay for the up-front licensing opportunity, without having to impact the budget for our MS1819 clinical timelines. In the long run, AzurRx is much better positioned to provide valuable products with significant market opportunities into the GI space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Entero Therapeutics Inc. (ENTO) Stock Research Links
Scroll down for more posts ▼